Ra Capital Management, L.P.'s Form 4 filing
Evommune, Inc. (EVMN) · filed Nov 12, 2025
- Accession no.
- 0001346824-25-000049
- Filed
- Nov 12, 2025
- Trade date
- Nov 7, 2025
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market purchases total $20.0M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2025 | Common Stock | CConversionAcquired | +1,517,329 | –F1 | – | 1,517,329 | Indirect | |
| Nov 7, 2025 | Common Stock | CConversionAcquired | +691,441 | –F1 | – | 691,441 | Indirect | |
| Nov 7, 2025 | Common Stock | PPurchaseAcquired | +1,157,096 | $16.00 | +$18,513,536 | 2,674,425 | Indirect | |
| Nov 7, 2025 | Common Stock | PPurchaseAcquired | +92,904 | $16.00 | +$1,486,464 | 784,345 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.
Remarks
Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.